2. >>Business Strategy

Jomed Stakes Out the US

By all accounts, the one piece missing from the puzzle for Jomed NV, the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Thus, most industry observers saw the value in Jomed's merger with Endosonics as providing it with a US sales and marketing infrastructure.

By all accounts the one piece missing from the puzzle for Jomed NV , the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Having successfully established itself in Europe and fresh on the heels of a well-received IPO, Jomed officials have known for years that they would, eventually, have to meet the companies it competes against in Europe, companies such as Guidant Corp. , Boston Scientific Corp. , and the Avecor Cardiovascular Inc. subsidiary of Medtronic Inc. , on their home turf. (See "Jomed's Rising Star," IN VIVO, April 1999 [A#1999800093.)

Thus, most industry observers saw the value of Jomed's deal for EndoSonics Corp. not in the latter's interventional ultrasound...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.